Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinzaparin prophylaxis for venous thromboembolism in metastatic colorectal cancer
2022-001534-11Phase 3Active
- Sponsor
- Grupo Gallego de Investigación en Tumores Digestivos
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of tinzaparin in metastatic colon cancer (mCRC) and venous thromboembolism (VTE), sponsored by Grupo Gallego de Investigación en Tumores Digestivos. Primary endpoint: Cumulative incidence of venous thromboembolism events. Started Sep 2022; status: active.
02
Drugs
tinzaparin
03
Conditions
metastatic colon cancer (mCRC)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2022-001534-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001534-11.